PROSTALUND AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.988 SEK | +2.07% |
|
+5.11% | -39.39% |
| Apr. 08 | ProstaLund AB Presents Two New Studies with Schelin Catheter | CI |
| Feb. 16 | ProstaLund AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 17.07M 1.57M | Sales 2022 | 17.41M 1.6M | Capitalization | 228M 21.03M |
|---|---|---|---|---|---|
| Net income 2021 | -7M -644K | Net income 2022 | -11M -1.01M | EV / Sales 2021 | 11.7 x |
| Net cash position 2021 | 13.04M 1.2M | Net cash position 2022 | 10.54M 970K | EV / Sales 2022 | 12.5 x |
| P/E ratio 2021 |
-24.4
x | P/E ratio 2022 |
-19
x | Employees | 7 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 47.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.07% | ||
| 1 week | +5.11% | ||
| Current month | -7.23% | ||
| 1 month | -14.83% | ||
| 3 months | -42.22% | ||
| 6 months | -54.47% | ||
| Current year | -39.39% |
1 week
0.91
1.10
1 month
0.911.26
Current year
0.911.90
1 year
0.914.01
3 years
0.916.72
5 years
0.917.94
10 years
0.9125.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 23-09-30 | |
Niclas Nyström
DFI | Director of Finance/CFO | 59 | Dec. 05 |
Johan Laven
SAM | Sales & Marketing | 51 | Dec. 31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul de Potocki
BRD | Director/Board Member | 62 | 23-10-11 |
| Director/Board Member | 59 | 23-04-30 | |
| Director/Board Member | 60 | 23-10-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.988 | +2.07% | 27 731 |
| 24-04-25 | 0.968 | -9.53% | 68,881 |
| 24-04-24 | 1.07 | +11.46% | 73,409 |
| 24-04-23 | 0.96 | -4.00% | 64,729 |
| 24-04-22 | 1 | +6.38% | 61,494 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:03 am EDT
More quotes
ProstaLund AB is a Sweden-based company that provides health care products and services. The Company develops and manufactures urological devices and treatments primarily for benign prostatic hyperplasia (BPH). The Company develops CoreTherm, a patented Thermotherapy treatment method for BPH, which takes approximately 6-15 minutes and offers long-term symptom relief. CoreTherm is used in hospitals and clinics in Sweden and worldwide.
Calendar
2024-05-16
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -39.39% | 6.8M | |
| -2.92% | 185B | |
| -3.80% | 105B | |
| -5.48% | 66.59B | |
| +11.22% | 54.66B | |
| +16.74% | 47.78B | |
| +4.06% | 41.26B | |
| +4.56% | 26.95B | |
| +1.64% | 26.37B | |
| +12.96% | 24.8B |
- Stock Market
- Equities
- PLUN Stock
